Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Depreciation & Amortization - Total (2016 - 2017)

Historic Depreciation & Amortization - Total for Altimmune (ALT) over the last 6 years, with Q1 2017 value amounting to $33007.0.

  • Altimmune's Depreciation & Amortization - Total fell 1245.06% to $33007.0 in Q1 2017 from the same period last year, while for Dec 2017 it was $33007.0, marking a year-over-year decrease of 7698.85%. This contributed to the annual value of $143437.0 for FY2016, which is 129.45% up from last year.
  • According to the latest figures from Q1 2017, Altimmune's Depreciation & Amortization - Total is $33007.0, which was down 1245.06% from $33066.0 recorded in Q4 2016.
  • Altimmune's Depreciation & Amortization - Total's 5-year high stood at $52602.0 during Q1 2013, with a 5-year trough of $32235.0 in Q3 2016.
  • Its 5-year average for Depreciation & Amortization - Total is $38264.3, with a median of $37106.0 in 2015.
  • As far as peak fluctuations go, Altimmune's Depreciation & Amortization - Total crashed by 3845.25% in 2013, and later skyrocketed by 1021.62% in 2016.
  • Quarter analysis of 5 years shows Altimmune's Depreciation & Amortization - Total stood at $43438.0 in 2013, then decreased by 15.54% to $36686.0 in 2014, then fell by 10.58% to $32806.0 in 2015, then increased by 0.79% to $33066.0 in 2016, then decreased by 0.18% to $33007.0 in 2017.
  • Its last three reported values are $33007.0 in Q1 2017, $33066.0 for Q4 2016, and $32235.0 during Q3 2016.